 Neurocrine Biosciences Inc NASDAQ: NBIX revealed topline data from its Phase 3 KINECT-HD study evaluating Ingrezza valbenazine for chorea associated with Huntingtons disease HD. The selective vesicular monoamine transporter 2 VMAT2 inhibitor is being investigated as a once-daily treatment in adult patients. 